– NCCN Guidelines aim to improve quality, effectiveness and efficiency of cancer care – BURLINGTON, Mass. and OXFORD, UK – February 20, 2018 – Blue Earth Diagnostics, a molecular...Read More ›
Welcome to Blue Earth Diagnostics
Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.